For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- It’s Time to Look at Supply Status, NHI-Market Price Gap to Revisit Drug Pricing: MHLW Official
April 11, 2022
- Generic Rates at Innovative Drug Makers Hovers at 60% Range: MHLW Data
April 11, 2022
- MHLW Set to Boost Recognition of Reporting System for Improper Drug Promotions
April 8, 2022
- Lower House OKs Economic Security Bill
April 8, 2022
- Extension of Emergency Approval Period Would Be Allowed Only Once: MHLW Official
April 7, 2022
- Moderna, Daiichi Sankyo Give mRNA Vaccine Updates: LDP Meeting
April 7, 2022
- Japan to Start Distributing Novavax Jab from Late May, If Approved
April 7, 2022
- MHLW Lays Out CDx Requirements for Use with Multiple Drugs
April 6, 2022
- Label Revisions Ordered for Somatropin, IFNβ-1a/1b Preparations
April 5, 2022
- SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
- Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
- MHLW Presents Policy for Use of “Specified Clinical Research” Data in Regulatory Submissions
April 4, 2022
- Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
- Japan PM Touts Proposed Emergency Approval Scheme as Bill Enters Diet Deliberations
April 1, 2022
- Fourth COVID Shots for Older Adults and High-Risk People: LDP Project Team
April 1, 2022
- 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
- Working Group Launched under Pharma Industry Vision Meets for 1st Time
March 31, 2022
- Vonvendi Label Revised for Routine Prophylaxis in VWD
March 30, 2022
- Vaccine Chief Horiuchi to Bow Out at March-End
March 30, 2022
- PMD Law Amendment Bill to Enter Diet Debate March 31, CDP’s Counter-Legislation Too
March 30, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…